Skip NavigationSkip to Content

Functional characterization of the protease of human endogenous retrovirus, K10: Can it complement HIV-1 protease?

  1. Author:
    Towler, E. M.
    Gulnik, S. V.
    Bhat, T. N.
    Xie, D.
    Gustschina, E.
    Sumpter, T. R.
    Robertson, N.
    Jones, C.
    Sauter, M.
    Mueller-Lantzsch, N.
    Debouck, C.
    Erickson, J. W.
  2. Author Address

    Towler EM NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Prot Chem Lab POB B Frederick, MD 21702 USA NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Prot Chem Lab Frederick, MD 21702 USA NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Struct Biochem Program Frederick, MD 21702 USA SmithKline Beecham Pharmaceut, Dept Mol Genet King Of Prussia, PA 19406 USA Univ Saarlandes Kliniken, Inst Med Mikrobiol & Hyg, Abt Virol D-66421 Homburg Germany
    1. Year: 1998
  1. Journal: Biochemistry
    1. 37
    2. 49
    3. Pages: 17137-17144
  2. Type of Article: Article
  1. Abstract:

    TO investigate the biochemical properties of the protease encoded by the human endogenous retrovirus, K10 (HERV-K), 213 amino acids of the 3'-end of the HERV-K protease (PR) open reading frame were expressed in Escherichia coli. Autocatalytic cleavage of the expressed polypeptide resulted in an 18.2 kDa protein which was shown to be proteolytically active against a fluorogenic peptide used as a substrate for HIV-1 protease. On the basis of sequence homology and molecular modeling, the 106 N-terminal amino acids of HERV-K PR were predicted to comprise a retroviral protease core domain. An 11.6 kDa protein corresponding to this region was expressed and shown to be a fully functional enzyme. The 11.6 kDa domain of HERV-K PR is unusually stable over a wide pH range, exhibits optimal catalytic activity between pH 4.0 and 5.0, and exists as a dimer at pH 7.0 with a K-d of 50 mu M. Like HIV-1 PR, the HERV-K PR core domain is activated by high salt concentrations and processes HIV-1 matrix-capsid polyprotein at the authentic HIV-1 PR recognition site. However, both the 18.2 and 11.6 kDa forms of HERV-K PR were highly resistant to a number of clinically useful HIV-1 PR inhibitors, including ritonavir, indinavir, and saquinavir. This raises the possibility that HERV-K PR may complement HIV-1 PR during infection, and could have implications for protease inhibitor therapy and drug resistance. [References: 26]

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel